Dr. Michael McCormack
Claim this profileWake Forest University Health Sciences
Studies Prostate Cancer
Studies Adenocarcinoma
14 reported clinical trials
44 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
2Adenocarcinoma
Stage IV
HER2 negative
PD-L1 positive
Affiliated Hospitals
Clinical Trials Michael McCormack is currently running
Radioactive Drug Therapy
for Prostate Cancer
This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.
Recruiting1 award Phase 216 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
More about Michael McCormack
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Michael McCormack has experience with
- Durvalumab
- Oxaliplatin
- MFOLFIRINOX
- Apalutamide
- M3814 (Peposertib)
- Hypofractionated Radiation Therapy
Breakdown of trials Michael McCormack has run
Prostate Cancer
Adenocarcinoma
Cancer
Urothelial Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael McCormack specialize in?
Michael McCormack focuses on Prostate Cancer and Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Michael McCormack currently recruiting for clinical trials?
Yes, Michael McCormack is currently recruiting for 9 clinical trials in Winston-Salem North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Michael McCormack has studied deeply?
Yes, Michael McCormack has studied treatments such as Durvalumab, Oxaliplatin, mFOLFIRINOX.
What is the best way to schedule an appointment with Michael McCormack?
Apply for one of the trials that Michael McCormack is conducting.
What is the office address of Michael McCormack?
The office of Michael McCormack is located at: Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States. This is the address for their practice at the Wake Forest University Health Sciences.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.